A review of entecavir in the treatment of chronic hepatitis B infection

References

• Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003;362:2089–94
   PubMed Web of Science ®Google Scholar
• Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatitis 2004;11:97–107
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Updated US Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR 2001;50(RR-11):1–42 <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5011a1.htm[Last accessed 04 October 2005]>
   Google Scholar
• Centers for Disease Control and Prevention. Disease burden from hepatitis A, B, and C in the United States; 2005 http:// www.cdc.gov/ ncidod/ diseases/hepatitis/resource/dz_burden02. htm [Last accessed 04 October 2005]
   Google Scholar
• Shaw T, Locarnini S. Entecavir for the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther 2004;2:853–71
   PubMedGoogle Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004;39:857–61
   PubMed Web of Science ®Google Scholar
• Custer B, Sullivan SD, Hazlet TK, et al. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004;38:S158–68
   PubMed Web of Science ®Google Scholar
• Rivkina A, Rybalov S. Chronic hepatitis B: current and future treatment options. Pharmacotherapy 2002;22:721–37
   PubMed Web of Science ®Google Scholar
• Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002;83:2059–73
   Google Scholar
• Bell SJ, Lau A, Thompson A, et al. Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients. J Clin Virol 2005;32:122–7
   PubMed Web of Science ®Google Scholar
• Kidd-Ljunggren K, Miyakawa Y, Kidd AH. Genetic variability in hepatitis B viruses. J Gen Virol 2002;83:1267–80
   Google Scholar
• Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001;120: 1828–53
   Google Scholar
• Wong DK, Cheung AM, O'Rourke K, et al. Effect of alphainterferon treatment in patients with hepatitis B e antigenpositive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312–23
   Google Scholar
• Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;29:971–5
   PubMed Web of Science ®Google Scholar
• Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997;113:1660–7
   PubMed Web of Science ®Google Scholar
• Lok AS, Chung HT, Liu VW, Ma OC. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993;105:1833–8
   PubMed Web of Science ®Google Scholar
• Krogsgaard K. The long-term effect of treatment with interferonalpha 2a in chronic hepatitis B [The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment]. J Viral Hepatitis 1998;5:389–97
   Google Scholar
• Piratvisuth T, Marcellin P, Lau G. ALT flares and sustained ALT response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2A(40kd), peginterferon-alfa 2A(40kd) plus lamivudine or lamivudine alone (abstract ). Hepatology 2004;40:656A
   Google Scholar
• Bonino F, Lau G, Marcellin P. The first detailed analysis of predictors of response in HBeAg-negative chronic hepatitis B: data from multicenter, randomized, partially double-blind study of peginterferon alfa-2A(40kd) alone or in combination with lamivudine versus lamivudine alone (abstract). Hepatology 2004;40:659A
   Google Scholar
• Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. New Engl J Med 2004;351:1206–17
   PubMed Web of Science ®Google Scholar
• Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. New Engl J Med 2005;352:2682–95
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. New Engl J Med 1999;341:1256–63
   PubMed Web of Science ®Google Scholar
• Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B [Asia Hepatitis Lamivudine Study Group]. New Engl J Med 1998;339:61–8
   PubMed Web of Science ®Google Scholar
• Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562–8
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37:748–55
   PubMed Web of Science ®Google Scholar
• Song BC, Suh DJ, Lee HC, et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803–6
   PubMed Web of Science ®Google Scholar
• Lee KM, Cho SW, Kim SW, et al. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepatitis 2002;9:208–12
   PubMed Web of Science ®Google Scholar
• Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B [Lamivudine Precore Mutant Study Group]. Hepatology 1999;29:889–96
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32: 847–51
   PubMed Web of Science ®Google Scholar
• Rizzetto M, Volpes R, Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. J Med Virol 2000;61:398–402
   Google Scholar
• Tassopoulos NC, Volpes R, Pastore G, et al. Post lamivudine treatment follow-up of patients with HBeAg negative chronic hepatitis [abstract]. J Hepatol 1999;30:117A
   Google Scholar
• Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30: 567–72
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. New Engl J Med 2003;348:808–16
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. New Engl J Med 2003;348:800–7
   PubMed Web of Science ®Google Scholar
• Peters M, Hann HW, Martin P, et al. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses YMDD mutant hepatitis B virus replication: 48 week preliminary analysis [abstract]. Hepatology 2002;36:374A
   PubMed Web of Science ®Google Scholar
• Schiff E, Willems B, Leung NW, et al. Addition of adefovir to lamivudine therapy results in significant reduction in HBV DNA and serum ALT in compensated chronic hepatitis B patients with YMDD variant HBV and a reduced response to lamivudine - 52 week result [abstract]. Hepatology 2002;36:636A
   Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG, et al. Long term efficacy and safety of adefovir dipivoxil (ADV) 10mg in the HBeAg+ chronic hepatitis B (CHB) patients: increasing serologic, virologic and biochemical response over time [abstract]. Hepatology 2004;40:655A
   Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. New Engl J Med 2005;352:2673–81
   PubMed Web of Science ®Google Scholar
• Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292–7
   PubMed Web of Science ®Google Scholar
• Locarnini S, Qi X, Arterburn S. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB) [abstract 36]. 40th Annual Meeting of the European Association for the Study of the Liver. Paris, France; 2005
   Google Scholar
• Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004;2:87–106
   PubMed Web of Science ®Google Scholar
• Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998;42:3200–8
   PubMed Web of Science ®Google Scholar
• Ruediger E, Martel A, Manwel N, et al. Novel 3'-deoxy analogs of the anti-HBV agent entecavir: synthesis of enantiomers from a single chiral epoxide. Tetrahedron Lett 2004;45:739–42
   Web of Science ®Google Scholar
• Yamanaka G, Wilson T, Innaimo S, et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother 1999;43: 190–3
   PubMed Web of Science ®Google Scholar
• Bifano M, Yan J, Xie J, et al. Hepatic impairment does not alter single-dose pharmacokinetics and safety of entecavir [abstract]. Hepatology 2004;40:663A
   Web of Science ®Google Scholar
• Baraclude TM (entecavir) package insert. Princeton (NJ): Bristol Myers Squibb Company; March 2005
   Google Scholar
• Zoulim F. Assessing hepatitis B virus resistance in vitro and molecular mechanisms of nucleoside resistance. Semin Liver Dis 2002;22(Suppl 1):23–31
   PubMedGoogle Scholar
• Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999;29:1863–9
   PubMed Web of Science ®Google Scholar
• Whalley SA, Murray JM, Brown D, et al. Kinetics of acute hepatitis B virus infection in humans. J Exp Med 2001;193:847–54
   PubMed Web of Science ®Google Scholar
• Wolters LM, Hansen BE, Niesters HG, et al. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis Br J Hepatol 2002;37:137–44
   Google Scholar
• Innaimo SF, Seifer M, Bisacchi GS, et al. Identification of BMS- 200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997;41:1444–8
   PubMed Web of Science ®Google Scholar
• Colonno RJ, Genovesi EV, Medina I, et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 2001;184:1236–45
   PubMed Web of Science ®Google Scholar
• Genovesi EV, Lamb L, Medina I, et al. Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother 1998;42:3209–17
   PubMed Web of Science ®Google Scholar
• Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986;47:451–60
   Google Scholar
• Wu TT, Coates L, Aldrich CE, et al. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 1990;175: 255–61
   PubMed Web of Science ®Google Scholar
• Dandri M, Burda MR, Will H, Petersen J. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology 2000;32:139–46
   PubMed Web of Science ®Google Scholar
• Moraleda G, Saputelli J, Aldrich CE, et al. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997;71:9392–9
   PubMed Web of Science ®Google Scholar
• Marion PL, Salazar FH, Winters MA, Colonno RJ. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother 2002;46:82–8
   PubMed Web of Science ®Google Scholar
• Foster WK, Miller DS, Marion PL, et al. Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection. Antimicrob Agents Chemother 2003;47: 2624–35
   PubMed Web of Science ®Google Scholar
• de Man RA, Wolters LM, Nevens F, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001;34:578–82
   PubMed Web of Science ®Google Scholar
• Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123: 1831–8
   PubMed Web of Science ®Google Scholar
• Chang TT, Hadziyannis S, Cianciara J, et al. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine [abstract]. Hepatology 2002;36:300A
   Web of Science ®Google Scholar
• Chang TT, Gish R, de Man RA, et al. Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: results of phase III study ETV-022 in nucleoside-naive patients [abstract]. Hepatology 2004;40:193A
   Web of Science ®Google Scholar
• Rosmawati M, Schiff E, Parana R, et al. Entecavir is superior to lamivudine at reducing HBV DNA in patients with chronic hepatitis B regardless of baseline alanine aminotransferase levels [abstract]. Hepatology 2004;40:656A
   Web of Science ®Google Scholar
• Shouval D, Lai CL, Cheinquer H, et al. Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naive HBeAg(-) chronic hepatitis B: results of phase III trial ETV-027 [abstract]. Hepatology 2004;40:728A
   Web of Science ®Google Scholar
• Lurie Y, Manns MP, Gish R. The efficacy of entecavir is similar regardless of disease-related baseline subgroups in treatment of nucleoside-naive, HBeAg(+) and HBeAg(-) patients with chronic hepatitis B [abstract 509]. 40th Annual Meeting of the European Association for the Study of the Liver. Paris, France; 2005
   Google Scholar
• Sherman M, Yurdaydin C, Sollano J, et al. Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory, HBeAg(+) chronic hepatitis B: results of phase III study ETV- 026 [abstract]. Hepatology 2004;40:664A
   Web of Science ®Google Scholar
• Gish R, de Man RA, Pedersen C. Sustained response off-treatment to entecavir and lamivudine after 48 weeks of treatment in nucleoside-naive, HBeAg(+) patients: 24-week follow-up results of phase 3 study ETV-022 [abstract 490]. 40th Annual Meeting of the European Association for the Study of the Liver. Paris, France; 2005
   Google Scholar
• Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004;48:3498–507
   PubMed Web of Science ®Google Scholar
• Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine [Lamivudine Clinical Investigation Group]. Hepatology 1998;27:1670–7
   PubMed Web of Science ®Google Scholar
• Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003;39:1085–9
   PubMed Web of Science ®Google Scholar
• Levine S, Hernandez D, Yamanaka G, et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002;46:2525–32
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Langley DR, Oliver AJ, et al. Hepatitis B virus resistance to entecavir involves novel changes in the viral polymerase [abstract 184]. Hepatology 2004;40:245A
   Web of Science ®Google Scholar
• Colonno RJ, Rose R, Levine SM, et al. Emergence of entecavir resistant hepatitis B virus after one year of therapy in phase II & III studies is only observed in lamivudine refractory patients [abstract]. Hepatology 2004;40:661A
   Web of Science ®Google Scholar
• Honkoop P, De Man RA. Entecavir: a potent new antiviral drug for hepatitis B. Expert Opin Invest Drugs 2003;12:683–8
   PubMed Web of Science ®Google Scholar
• Sollano J, Schiff E, Carrilho F, et al. Entecavir is well-tolerated for treatment of chronic hepatitis B: phase III safety analysis in nucleoside-naive and lamivudine-refractory patients [abstract]. Hepatology 2004;40:665A
   Web of Science ®Google Scholar
• Colonno RJ, Discotto L, Gong YF, et al. Combination studies involving entecavir and HIV nucleoside reverse transcriptase inhibitors showed no antagonistic effects on HBV or HIV activity in vitro [abstract]. J Hepatol 2004;40(Suppl 1):110
   PubMedGoogle Scholar
• Ying C, De Clerq E, Colonno RJ, Neyts J. Ribavirin and mycophenolic acid potentiate the activity of entecavir against hepatitis B virus [abstract]. Antiviral Res 2004;62:A47
   PubMed Web of Science ®Google Scholar
• Feld J, Locarnini S. Antiviral therapy for hepatitis B virus infections: new targets and technical challenges. J Clin Virol 2002;25:267–83
   PubMed Web of Science ®Google Scholar
• Akarca US, Ersoz G, Gunsar F, et al. Interferon-lamivudine combination is no better than lamivudine alone in anti-HBe- positive chronic hepatitis B. Antiviral Ther 2004;9:325–34
   PubMed Web of Science ®Google Scholar
• Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123–9
   PubMed Web of Science ®Google Scholar
• Peters MG, Hann Hw H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine- resistant chronic hepatitis B. Gastroenterology 2004; 126: 91–101
   PubMed Web of Science ®Google Scholar
• Sung J, Lai CL, Zeuzem S, et al. A randomized double blind Phase II study of lamivudine compared to lamivudine plus adefovir dipivoxil for treatment-naive patients with chronic hepatitis B [oral presentation]. 38th Annual Meeting of the European Association for the Study of the Liver. Istanbul, Turkey; 2003
   Google Scholar
• Delaney WEt, Yang H, Miller MD, et al. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother 2004;48:3702–10
   PubMed Web of Science ®Google Scholar